Now showing items 1-2 of 2

    • Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. 

      Yap, TA; Macklin-Doherty, A; Popat, S (2017-01)
      The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and ...
    • Telemedicine During the COVID-19 Pandemic: Impact on Care for Rare Cancers. 

      Smrke, A; Younger, E; Wilson, R; Husson, O; Farag, S; Merry, E; Macklin-Doherty, A; Cojocaru, E; Arthur, A; Benson, C; Miah, AB; Zaidi, S; Gennatas, S; Jones, RL (2020-07)
      <h4>Purpose</h4>Many patients with cancer, often those with rare cancers such as sarcomas, travel long distances to access expert care. The COVID-19 pandemic necessitated widespread changes in delivery of cancer care, ...